NVO Jan 2024 125.000 put
- Globe Newswire
Once-weekly insulin icodec demonstrates superior reduction in HbA1c in combination with a dosing guide app versus once-daily basal insulin in people with type 2 diabetes in ONWARDS 5 phase 3a trial
Bagsværd, Denmark, 3 October 2022 – Novo Nordisk today announced headline results from the ONWARDS 5 phase 3a trial with once-weekly insulin icodec in people with type 2 diabetes. The ONWARDS 5 trial was a 52-week, open-label efficacy and safety treat-to-target trial investigating once-weekly insulin versus once-daily basal insulin (insulin degludec or insulin glargine U100/U300) in 1,085 insulin-naïve people with type 2 diabetes in a clinical practice setting including fewer trial visits compar
- Zacks
The Zacks Analyst Blog Highlights Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron
Novo Nordisk, Suncor Energy, Nasdaq, W.W. Grainger and Textron are included in this Analyst Blog.
- Zacks
Top Analyst Reports for Novo Nordisk, Suncor Energy, & Nasdaq
Today's Research Daily features new research reports on 12 major stocks, including Novo Nordisk A/S (NVO), Suncor Energy Inc. (SU) and Nasdaq, Inc. (NDAQ).
